Accuray

Accuray, Inc. is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes CyberKnife and Tomo Therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy. The company was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Accuray reports strong Q1 2023 earnings and focuses on global expansion

Accuray's Q1 2023 earnings call highlighted strong financial performance, with significant revenue growth and increased system orders. The company is focused on driving profitability expansion and expanding patient access to its technologies worldwide. While facing challenges in managing backlog and addressing performance in China, Accuray is actively pursuing opportunities for margin expansion and business growth.

Accuray delivers record Q2 performance, eyes growth opportunities ahead

Accuray's Q2 2023 performance highlighted record system deliveries and strong order growth, with a focus on radiation oncology services.
Despite challenges in revenue decline and backlog, strategic wins and progress in key regions position the company for future growth.
Opportunities lie in market expansion in the Americas, strategic wins in key regions, and advancements in China.
Maintaining growth momentum, addressing revenue challenges, and capitalizing on opportunities are key focus areas for Accuray.

Accuray reports strong Q3 earnings, eyes global expansion and partnerships

Accuray's Q3 2023 earnings call showcased robust financial performance, strategic initiatives to drive profitability, and a commitment to global expansion. Despite challenges in product positioning and market competition, the company's focus on innovation and partnerships positions it well for future growth and market leadership.

Accuray reports 8% revenue growth, eyes margin expansion and growth

Accuray's Q4 2023 performance showed revenue growth, strong demand for Radixact, and strategic order wins. While facing challenges in product margins and supply chain, the company aims for margin expansion and growth opportunities in the second half of FY '24. Implementation of a new ERP system is expected to drive operational efficiencies and profitability insights.

Accuray reports strong Q1 earnings, eyes growth in China and India

Accuray delivered a robust Q1 performance with revenue and EBITDA growth, backed by strategic wins in key markets like China and India. The company's focus on new product innovations and cost optimization efforts contributed to its positive results. While challenges related to inflation exist, Accuray remains optimistic about reimbursement changes and market opportunities.

Accuray reports strong Q2 performance with growth opportunities ahead

Accuray's Q2 2024 showcased robust order growth, service revenue increase, and global demand strength. The company is focused on margin expansion and new product market clearances for future growth.

Accuray faces challenges in Q3 2024 but remains optimistic

Accuray's Q3 2024 performance was impacted by challenges but showed resilience with global order growth and strategic focus on long-term goals. Despite revised guidance, the company remains optimistic about future growth drivers and is prepared for gradual recovery post-COVID.

Accuray reports robust Q1 performance and raises FY '25 guidance

Accuray's Q1 2025 performance reflects strong revenue growth, margin expansion efforts, and positive market reception for its innovative products and services.
While facing challenges in certain markets and regulatory timelines, the company remains optimistic about future revenue trends and growth opportunities globally.
By raising its revenue guidance and focusing on operational efficiency, Accuray aims to capitalize on market opportunities and navigate potential challenges effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accuray, Inc. is a radiation therapy company, which engages in manufacturing medical equipment. It develops, manufactures, sells, and supports medical solutions. The company was founded by John R. Adler in 1990 and is headquartered in Madison, WI.

The radiation-oncology machine company saw shares rise after it released an earnings report.

Why Shares of Accuray Jumped Thursday

Accuray's revenue did fall year-over-year as reported, but the company beat expectations and product revenue reached a new all-time high with 8% year-over-year constant-currency growth. Orders grew sequentially at a double-digit rate and net orders doubled; Accuray still has work to do to reach $100M in gross quarterly orders.

Accuray Achieves Record Product Revenue, But There's Much Work Still To Be Done

Accuray (ARAY) delivered earnings and revenue surprises of 33.33% and 7.98%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Accuray (ARAY) Reports Q2 Loss, Tops Revenue Estimates

SUNNYVALE, Calif. , Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Robert C.

Robert C. Kill Joins Accuray Board of Directors

Delivered strong Q2 performance amidst challenging macroenvironment; Reiterate fiscal year guidance     SUNNYVALE, Calif. , Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter of fiscal 2023 ended December 31, 2022.

Accuray Reports Fiscal 2023 Second Quarter Financial Results

Center believes the CyberKnife System is the #1 tool for delivery of advanced radiosurgery treatments Selected the latest generation CyberKnife S7™ System to increase the number of indications they can treat throughout the body, and the patients they can help SUNNYVALE, Calif. , Jan. 26, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the European Radiosurgery Center Munich has selected a second CyberKnife ® System, the latest generation CyberKnife S7™ System, to enable their team to treat the high volume of patients they see in their practice who would benefit from the extremely precise radiation treatments it delivers.

European Radiosurgery Center Munich Invests in Second Accuray CyberKnife® System to Support the Demand for High-Precision Radiosurgery Treatments

SUNNYVALE, Calif. , Jan. 18, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2023, ended December 31, 2022, after the market close on February 1, 2023.

Accuray to Report Second Quarter Fiscal 2023 Financial Results on February 1, 2023

Auckland Radiation Oncology Selected the Latest-Generation CyberKnife S7™ System to Deliver Precise Treatments More Quickly, so Patients Can Rapidly Return to the Activities They Enjoy SUNNYVALE, Calif. , Jan. 17, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Auckland Radiation Oncology (ARO) is the first center in New Zealand to treat patients with the CyberKnife ® System, a robotic radiation therapy device known for delivering treatments with sub-millimeter precision and accuracy in typically 1 to 5 outpatient sessions.

Accuray Announces First Patient Treatments in New Zealand With the CyberKnife® System, the World's Only Robotic Radiation Therapy Delivery Device

Company to Take Part in Fireside Chat Wednesday, January 18, 2023 at 7:00am PST/10:00am EST SUNNYVALE, Calif. , Jan. 10, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the B.

Accuray to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

SUNNYVALE, Calif. , Nov. 28, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that its commitment to delivering better, faster cancer treatment technology and superior service is resulting in highly satisfied customers.

Accuray Receives IMV Award for Best In Service in Radiation Oncology for 2022

Hospital Adds Accuray ClearRT™ Helical Fan-Beam kVCT Imaging and Synchrony® Technologies to Both Radixact Systems, Creating the Ultimate System for Personalized Cancer Care SUNNYVALE, Calif. , Nov. 16, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Oscar Lambret Center in Lille, France has installed its second Radixact ® System and the hospital's fifth Accuray radiation therapy delivery system.

Oscar Lambret Center in France Installs Second Accuray Radixact® System, the Hospital's Fifth Accuray Radiation Therapy Delivery System

Despite solid product demand, Accuray (ARAY) reports an overall soft Q1 performance.

Accuray's (ARAY) Q1 Earnings and Revenues Lag Estimates

Accuray Incorporated (NASDAQ:ARAY ) Q1 2023 Results Conference Call November 2, 2022 4:30 AM ET Company Participants Ken Mobeck - Vice President of Finance and Investor Relations Suzanne Winter - Chief Executive Officer Ali Pervaiz - Chief Financial Officer Conference Call Participants Charlie Montang - Lake Street Capital Josh Jennings - Cowen Neil Chatterji - B. Riley Sam Eiber - BTIG Jason Wittes - Loop Capital Operator Good afternoon, and welcome to the Accuray First Quarter 2023 Financial Results Conference Call.

Accuray Incorporated (ARAY) Q1 2023 Earnings Call Transcript

Accuray (ARAY) delivered earnings and revenue surprises of -500% and 8.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Accuray (ARAY) Reports Q1 Loss, Misses Revenue Estimates

Strong customer demand. Navigating FX and Supply Chain Challenges.

Accuray Reports Fiscal 2023 First Quarter Financial Results

SUNNYVALE, Calif. , Nov. 1, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the CNNC-Accuray joint venture Tomo® C radiation therapy system for the Type B market has been submitted to the Chinese National Medical Products Administration (NMPA).

Accuray Announces Tomo® C Registration Submission to China's National Medical Products Administration

SUNNYVALE, Calif. , Oct. 26, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved reimbursement for the CyberKnife ® System for the treatment of trigeminal neuralgia (TN).

New Reimbursement Approved by the Japanese Ministry of Health, Labor and Welfare for the Accuray CyberKnife® System to Treat Trigeminal Neuralgia, a Condition Often Causing Severe Facial Pain

General Electric

Collaboration places emphasis on personalized medicine; brings together key precision diagnostic and treatment delivery tools aimed at creating shorter, more comfortable and more effective treatments for patients CHICAGO and SUNNYVALE, Calif. , Oct. 21, 2022 /PRNewswire/ -- GE Healthcare and Accuray Incorporated (NASDAQ: ARAY) announced today that they have signed a global commercial collaboration agreement designed to provide solutions that make it possible for more healthcare teams around the world to tailor patients' care at every stage of their treatment journey.

GE Healthcare and Accuray Collaborate to Expand Access, Advance the Practice of Precision Radiation Therapy

SUNNYVALE, Calif. , Oct. 19, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2023, ended September 30, 2022, after the market close on November 2, 2022.

Accuray to Report First Quarter Fiscal 2023 Financial Results on November 2, 2022

Accuray's (ARAY) latest automated breast cancer treatment package for the Radixact System is expected to extend and improve the quality of patients' lives.

Accuray's (ARAY) New Treatment Package to Boost Patient Outcome

SUNNYVALE, Calif. , Oct. 13, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company, in partnership with C-RAD AB (NASDAQ Stockholm: CRAD B), will showcase an important new option for improving the care of people diagnosed with breast cancer during the 2022 ASTRO (American Society for Radiation Oncology) Annual Meeting in San Antonio, Texas, October 23 – 26, 2022.

Accuray and C-RAD Unveil Automated Breast Cancer Treatment Package for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting

Latest research published in The Lancet Oncology: suggests bladder side effects were experienced half as often with CyberKnife SBRT as with conventional linear accelerator delivered SBRT two years after treatment Almost 20 years of global clinical data: shows the non-surgical CyberKnife platform provides excellent disease control with low rates of toxicity for men with prostate cancer SUNNYVALE, Calif. , Oct. 11, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that results of the PACE-B – Prostate Advances in Comparative Evidence – trial were published in The Lancet Oncology , a leading global peer-reviewed oncology journal.

Data Published in The Lancet Oncology Indicate Men With Prostate Cancer Treated With the Accuray CyberKnife® Platform Experienced a Lower Incidence of Bladder Side Effects Than Those Treated With Conventional Linear Accelerators

SUNNYVALE, Calif. , Oct. 6, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host a key opinion leader (KOL) discussion with analysts and investors on Monday, October 24, 2022, in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting.

Accuray to Host Meeting with Analysts and Investors at ASTRO on October 24, 2022

World's Only Robotic Radiation Therapy Device Delivers Extremely Precise Treatments in Just 1 to 5 Out-Patient Sessions SUNNYVALE, Calif. , Sept. 30, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company is expanding its global footprint with the introduction of its CyberKnife ® platform in Africa, making it possible for more patients to obtain access to the extremely precise stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments the system delivers.

Accuray Announces First CyberKnife® Systems in Africa, Providing a New Option and Hope for Potentially Life-Saving Radiation Treatments for More Cancer Patients

Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.

News for Accuray Stock (ARAY)